Special Issue

Oropouche Virus (OROV): An Emerging Peribunyavirus (Bunyavirus)

Message from the Guest Editors

This Special Issue on *Viruses* will address topics addressing the Oropouche virus, including biological aspects such as virology, genetic variation, immunology, and host factors. Articles on the epidemiology of Oropouche fever are requested, including insect vectors and natural hosts, transmission dynamics, geographical distribution, natural history, and relationships with other related arboviruses. Clinical articles will discuss the presentation, diagnosis, treatment, prevention, and potential for vaccine and antiviral medication development. Experimental infections in animal models and cell culture are welcome. Articles discussing any aspect of the 2023-2024 OROV epidemic are welcomed, and, in particular, the occurrence of Oropouche fever in pregnancy and its association with obstetrical disease, fetal loss, vertical transmission, congenital microcephaly, and fetal malformations. Submissions can be original research articles, reviews, communications, viewpoints, case reports, and editorials. Illustrative and graphic materials, including photographs, are encouraged whenever possible.

Guest Editors

Dr. David A. Schwartz

Perinatal Pathology Consulting, Atlanta, GA, USA

Prof. Dr. André Ricardo Ribas Freitas

Department of Epidemiology, São Leopoldo Mandic Medical School, Campinas 13045-755, SP, Brazil

Deadline for manuscript submissions

1 June 2026



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/216348

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

